443 related articles for article (PubMed ID: 22623230)
1. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
[TBL] [Abstract][Full Text] [Related]
2. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
Gajos G; Rostoff P; Undas A; Piwowarska W
J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
[TBL] [Abstract][Full Text] [Related]
3. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
[TBL] [Abstract][Full Text] [Related]
5. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
[TBL] [Abstract][Full Text] [Related]
7. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
[TBL] [Abstract][Full Text] [Related]
9. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
[TBL] [Abstract][Full Text] [Related]
10. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
12. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
Liu XL; Wang ZJ; Yang Q; Ge HL; Gao F; Liu YY; Shi DM; Zhao YX; Zhou YJ
Chin Med J (Engl); 2010 Nov; 123(22):3178-83. PubMed ID: 21163112
[TBL] [Abstract][Full Text] [Related]
14. [Omega-3--clopidogrel can help!].
Huczek Z
Kardiol Pol; 2012; 70(5):446. PubMed ID: 22623231
[No Abstract] [Full Text] [Related]
15. α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.
Peace AJ; Mangiacapra F; Bailleul E; Delrue L; Dierickx K; Conte M; Puymirat E; Fraeymans AL; Meeus P; Bartunek J; Volpe M; Barbato E
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1314-9. PubMed ID: 24723553
[TBL] [Abstract][Full Text] [Related]
16. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
17. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
[TBL] [Abstract][Full Text] [Related]
18. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
19. Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Dai ZL; Chen H; Wu XY
Zhong Xi Yi Jie He Xue Bao; 2012 Jun; 10(6):647-54. PubMed ID: 22704413
[TBL] [Abstract][Full Text] [Related]
20. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]